HCC Academy of Immunotherapy (Ina-CIT): Clinician roles to change HCC patient’s outcomes in Cancer Immunotherapy Era, conducted on 01 October 2022, 09:30 AM, at Mandarin Oriental Hotel Jakarta, which was conducted in Hybrid mode and participated by 31 HCPs offline and 7 HCPs online.
In the 1st scientific session moderated by Dr. dr. Andri Sanityoso, SpPD, K-GEH, FINASIM; Prof. Masatoshi Kudo, MD, PhD delivered an interesting topic “Recent Progress and Future Directions of HCC Systemic Therapies: The Need for HCC-specific Targets and Regimens”.
In this session Prof Kudo emphasizes that to obtain “Wide benefit”, we should select the regimen which has lower PD rate and higher CR rate in addition to better OS HR and better PFS HR.
Prioritized requirement for 1st line systemic therapy for uHCC:
- Overall survival (OS) prolongation
- IMbrave150 ABC : 19.2 months [HR 0.66 (0.52–0.85)] and 24 months [HR 0.53 (0.35–0.80)] for china sub-population
- Good direct anti-tumor effect (PFS, ORR)
- PFS: 6.9 months [HR 0.65 (0.53, 0.81), P = 0.0001]
- ORR: RECIST 1.1 → 30%; HCC mRECIST → 35%
- Median DOR: RECIST 1.1 → 18.1 months ; HCC mRECIST → 16.3 months
- Preservation of liver function up to 30 cycles
- Preservation of QOL
- PRO: time to QoL deterioration ABC therapy is around 11.2 months [HR=0.63 (0.46 – 0.85)]
- High transition rate to subsequent therapy
- ABC as 1st line therapy results in > 70% Patients eligible for 2nd line therapy due to preserved liver function in comparison to TKI as 1st line only result in < 50 % Patients eligible for 2nd line therapy, hence longer survival rate for subsequent therapies.
View of Prof. Kudo is here.